Free Newsletter
ALSO NOTED: Study questions "black box" on droperidol; Amilyn gets pen-injector OK;
> A new Mayo Clinic study seems to show that the FDA's "black box" warning of irregular heartbeat on the antinausea drug droperidol may be unnecessary. Report
> Amilyn Pharmaceuticals got the FDA nod for its pen-injector form of the diabetes drug Symlin. Release
> Lupin of India bought Rubamin Lab, a contract manufacturer, for an undisclosed amount. Report
And Finally... Do TV characters typically name-drop prescription drugs? Apparently so: Brand-name drugs were part of the TV-series plots some 705 times so far this year--and though only one drug maker admits to product placement marketing, the rest may not be far behind. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: